Document is current
Any future updates will be listed below
-
Authors
Balakrishnan, Maya
George, Rollin
Sharma, Ashish
Graham, David Y.
Malaty, Hoda M.
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK56338)
Cancer Prevention and Research Institute of Texas (PP160089)
- License Information
-
More Information
Article History
Received: 9 January 2018
Accepted: 6 March 2018
First Online: 15 March 2018
Compliance with ethical standards
:
: Dr. Graham is a consultant for RedHill Biopharma regarding novel <i>H. pylori</i> therapies and has received research support for culture of <i>Helicobacter pylori</i> and is the PI of an international study of the use of antimycobacterial therapy for Crohn’s disease. He is also a consultant for BioGaia in relation to probiotic therapy for <i>H. pylori</i> infection and for Takeda in relation to <i>H. pylori</i> therapies. The other authors have nothing to disclose.
